The objective of the present study is to analyze the cost-effectiveness of percutaneous coronary intervention (PCI) using TAXUS stents compared to the costs of coronary artery bypass surgery (CABG) in patients with multivessel coronary artery disease (CAD) in the first 5 years and then 10 years after intervention. Multivessel PCI or CABG was performed in 114 or 93 patients, respectively. Clinical outcomes, in terms of incidence of acute myocardial infarction (AMI), all-cause death, target vessel revascularization (TVR) and stroke, resource use and costs are analyzed prospectively over a 5 and 10-year follow-up (FUP) period. Overall costs consist of the baseline costs of the index procedure (PCI or CABG), clinical and angiographic procedure-related treatments during the entire FUP. The primary endpoint is cost-effectiveness and clinical effectiveness, defined as the reduction of the composite of major adverse cardiac and cerebrovascular events (MACCE).
Study Type
OBSERVATIONAL
Enrollment
207
invasive treatment of coronary artery disease
Medical University of Vienna, Dept. of Cardiology
Vienna, Austria
Cost-effectiveness of percutaneous coronary intervention with Taxus stents compared to CABG in patients with multivessel coronary artery disease.
Time frame: in-hospital phase (up to 3 weeks)
Cost-effectiveness of percutaneous coronary intervention with Taxus stents compared to CABG in patients with multivessel coronary artery disease.
Time frame: 6 months
Cost-effectiveness of percutaneous coronary intervention with Taxus stents compared to CABG in patients with multivessel coronary artery disease.
Time frame: 12 months
Cost-effectiveness of percutaneous coronary intervention with Taxus stents compared to CABG in patients with multivessel coronary artery disease.
Time frame: 5 years
Cost-effectiveness of percutaneous coronary intervention with Taxus stents compared to CABG in patients with multivessel coronary artery disease.
Time frame: 10 years
Occurrence of MACCE, defined as cardiac death, nonfatal myocardial infarction, target vessel revascularization and stroke
Time frame: 6 months
Rate of target vessel revascularization
Time frame: 6 months
Occurrence of non-fatal acute myocardial infarction
Time frame: 6 months
Occurrence of cardiac death
Time frame: 6 months
Calculation of the total costs
Time frame: in-hospital phase (up to 3 weeks)
Occurrence of MACCE, defined as cardiac death, nonfatal myocardial infarction, target vessel revascularization and stroke
Time frame: 12 months
Occurrence of MACCE, defined as cardiac death, nonfatal myocardial infarction, target vessel revascularization and stroke
Time frame: 5 years
Occurrence of MACCE, defined as cardiac death, nonfatal myocardial infarction, target vessel revascularization and stroke
Time frame: 10 years
Rate of target vessel revascularization
Time frame: 12 months
Rate of target vessel revascularization
Time frame: 5 years
Rate of target vessel revascularization
Time frame: 10 years
Occurrence of non-fatal acute myocardial infarction
Time frame: 12 months
Occurrence of non-fatal acute myocardial infarction
Time frame: 5 years
Occurrence of non-fatal acute myocardial infarction
Time frame: 10 years
Occurrence of cardiac death
Time frame: 12 months
Occurrence of cardiac death
Time frame: 5 years
Occurrence of cardiac death
Time frame: 10 years
Calculation of the total costs
Time frame: 6 months
Calculation of the total costs
Time frame: 12 months
Calculation of the total costs
Time frame: 5 years
Calculation of the total costs
Time frame: 10 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.